---
title: Improve language processing and behavior
nct_id: NCT07449117
phase: NA
status: RECRUITING
sponsor: Masaryk University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07449117"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07449117"
last_fetched: "2026-05-10T14:07:22.145Z"
source: "Parkinson's Pathways (curated)"
---
# Improve language processing and behavior

**Goal (in five words):** Improve language processing and behavior

**Official Title:** Immediate Effects of Non-invasive Temporal Interference Stimulation Targeting Deep Fronto-Striatal Structures on Language Processing and Behavioral Performance in Patients With Neurodegenerative Diseases

**Trial ID:** [NCT07449117](https://clinicaltrials.gov/study/NCT07449117)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Masaryk University
- **Target Enrollment:** 70 participants
- **Start Date:** 2026-03
- **Completion Date:** 2027-12
- **Conditions:** Mild Cognitive Impairment (MCI) Amnestic, Lewy Body Disease With Mild Cognitive Impairment, Parkinson's Disease With Mild Cognitive Impairment
- **Interventions:** Active Temporal Interference Stimulation (TIS), Placebo / Sham TIS
- **Intervention Types:** DEVICE

## Summary For Families

It aims to change activity in deep frontal and striatal brain circuits to produce immediate improvements in language processing and behavioral performance for people with mild cognitive impairment related to Parkinson's, Lewy body disease, or amnestic MCI. The approach, temporal interference stimulation, sends two high-frequency electrical currents through scalp electrodes that intersect deep in the brain to create a low-frequency modulation that can adjust neural firing in those targeted frontal and striatal areas. Participants receive either active TIS or a sham procedure so researchers can compare real versus placebo effects, and because TIS targets cognitive circuits it is not meant to replace or directly interact with dopaminergic drugs like levodopa. The study is looking for people aged 60 to 80 with MCI-PD, MCI-LB, or aMCI, and excludes those with severe psychiatric illness, other neurologic diseases, major head trauma, uncompensated medical or cancer conditions, or MRI-incompatible metal implants.

## Eligibility

- **Minimum age:** 60 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Possible or probable Mild Cognitive Impairment with Lewy Bodies (MCI-LB), in Parkinson's Disease (MCI-PD) or Amnestic Mild Cognitive Impairment (aMCI).

Exclusion Criteria:

* Any severe psychiatric disorder.
* History of other neurological diseases affecting the central nervous system.
* Severe head trauma.
* Uncompensated internal or oncological disease.
* Presence of MRI-incompatible metal in the body (e.g., pacemaker).
```

## Locations (1)

- CEITEC MU (Central European Institute of Technology, Masaryk University), Brno, South Moravian, Czechia _(49.1952, 16.6080)_
  - Ľubomíra Nováková, Ph.D. — (CONTACT) — +420 549 497 766 — lubomira.novakova@ceitec.muni.cz
  - Ľubomíra Nováková, Ph.D. — (PRINCIPAL_INVESTIGATOR)
  - Irena Rektorová, Prof. Ph.D. — (SUB_INVESTIGATOR)
  - Jiří Mekyska, Ph.D. — (SUB_INVESTIGATOR)
  - Jan Fousek, Ph.D. — (SUB_INVESTIGATOR)

## Central Contacts

- Ľubomíra Nováková, Ph.D. — (CONTACT) — +420 549 497 766 — lubomira.novakova@ceitec.muni.cz

---

*Canonical: https://parkinsonspathways.com/trial/NCT07449117*  
*HTML version: https://parkinsonspathways.com/trial/NCT07449117*  
*Source data: https://clinicaltrials.gov/study/NCT07449117*